This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Reduced Pain, Opioid Use, And Opioid-Related Adverse Events In Patients Receiving EXPAREL® Compared With Patients Receiving Bupivacaine HCl As A Component Of Multimodal Therapy

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the publication of results from a pooled analysis of nine clinical trials across five surgical models that compared cumulative pain scores, opioid consumption and occurrence of opioid-related adverse events (ORAEs) following administration of EXPAREL ® (bupivacaine liposome injectable suspension) or bupivacaine HCl. EXPAREL is a non-opioid local analgesic indicated for administration into the surgical site to produce postsurgical analgesia.

Notably, the results of the pooled analysis demonstrated that EXPAREL in a multimodal setting was associated with a statistically significant:

  • Reduction in cumulative pain scores through 72 hours ( P=0.039)
  • Longer time to first opioid rescue ( P<0.0001)
  • Decrease in opioid requirements and incidence of ORAEs
    • Significant reduction in opioid use ( P<0.0001)
    • Thirty-six percent of bupivacaine HCl patients experienced at least one ORAE compared to 20 percent of EXPAREL patients ( P<0.0001)

“This pooled analysis of over 900 clinical trial patients revealed not only improved pain scores with EXPAREL but also a statistical effect on several aspects of the opioid burden, compared to patients randomized to bupivacaine HCl in a multimodal setting,” said Joseph Dasta, MSc, FCCM, FCCP, RPh, Adjunct Professor at the University of Texas College of Pharmacy, and lead author on the paper. “This EXPAREL-based approach to multimodal pain management, which minimizes exposure to opioids and thus their related adverse events, has the potential to have important economic consequences.”

This analysis pools data from a total of 503 patients who received a single administration of EXPAREL at doses up to 266 mg compared with 409 patients who received bupivacaine HCl at doses up to 200 mg; surgical models included inguinal hernia repair, total knee arthroplasty, hemorrhoidectomy, bunionectomy and breast augmentation. The most frequently reported adverse events in both treatment groups were nausea, constipation and vomiting.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs